MTEM Logo

Molecular Templates, Inc. (MTEM) 

NASDAQ
Market Cap
$2.21M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
132 of 774
Rank in Industry
86 of 433

Largest Insider Buys in Sector

MTEM Stock Price History Chart

MTEM Stock Performance

About Molecular Templates, Inc.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and …

Insider Activity of Molecular Templates, Inc.

Over the last 12 months, insiders at Molecular Templates, Inc. have bought $587,500 and sold $845,833 worth of Molecular Templates, Inc. stock.

On average, over the past 5 years, insiders at Molecular Templates, Inc. have bought $14.28M and sold $7.95M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BIOTECH TARGET N V (10 percent owner) — $2.35M.

The last purchase of 250,000 shares for transaction amount of $587,500 was made by BIOTECH TARGET N V (10 percent owner) on 2024‑04‑02.

List of Insider Buy and Sell Transactions, Molecular Templates, Inc.

2024-11-14Sale10 percent owner
1.28M
20.6511%
$0.66$845,8330.00%
2024-04-02Purchase10 percent owner
250,000
5.7535%
$2.35$587,500-26.32%
2023-07-17Purchase10 percent owner
4.26M
6.4706%
$0.47$2M-53.81%
2022-06-16PurchaseSee remarks
30,000
0.0536%
$0.82$24,477-34.57%
2022-06-13Purchase
62,000
0.1065%
$0.89$55,180-42.39%
2022-06-13Purchase
62,000
0.1065%
$0.89$55,180-42.39%
2022-05-16Purchase
200,000
0.3584%
$1.18$236,200-49.57%
2022-01-06Purchase10 percent owner
200,000
0.3471%
$4.04$807,180-77.97%
2021-09-21Purchase10 percent owner
750,000
1.2249%
$6.00$4.5M-61.39%
2021-09-16Purchase10 percent owner
100,000
0.176%
$6.13$613,000-58.39%
2021-07-27Purchase10 percent owner
75,000
0.1333%
$7.09$531,840-52.96%
2021-07-26Purchase10 percent owner
80,000
0.141%
$7.00$559,816-52.55%
2021-07-20Purchase10 percent owner
125,000
0.2177%
$7.13$891,675-52.88%
2021-07-19Purchase10 percent owner
119,382
0.2095%
$6.96$830,827-51.20%
2021-06-28SaleSee remarks
2,770
0.0049%
$8.36$23,157-54.01%
2021-04-19Purchase10 percent owner
40,852
0.0709%
$8.08$329,941-27.38%
2021-04-15Purchase10 percent owner
150,000
0.2646%
$8.62$1.29M-30.65%
2021-04-14Purchase10 percent owner
150,000
0.2714%
$8.37$1.26M-26.73%
2021-04-13Purchase10 percent owner
100,000
0.1769%
$7.81$780,970-23.00%
2021-04-12Purchase10 percent owner
50,000
0.0914%
$8.02$400,830-22.31%

Insider Historical Profitability

<0.0001%
BIOTECH TARGET N V10 percent owner
0
0%
$0.34321<0.0001%
BB BIOTECH AG
11192003
169.991%
$0.3410<0.0001%
SUTTER HILL VENTURES10 percent owner
4715398
71.6204%
$0.3422
Hirsch David
4199035
63.7775%
$0.3420+10.35%
BIRD JEFFREY Wdirector
3940573
59.8518%
$0.3433+58.99%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bellevue Group$2.31M15.641.03M0%+$00.04
Bvf Inc Il$1.17M7.93522,238-1.84%-$21,952.000.01
Silverarc Capital Management Llc$794,322.005.39354,6080%+$00.01
Adage Capital Partners Gp L L C$576,130.003.91257,201-12.15%-$79,661.09<0.01
Caxton Corp$306,580.002.08136,8660%+$01.75
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.